Cardiol Therapeutics Achieves 50% Patient Enrollment in Pivotal Phase III MAVERIC Trial
Summary
Cardiol Therapeutics announced it has surpassed 50% patient enrollment in its pivotal Phase III MAVERIC trial for recurrent pericarditis, marking a key de-risking milestone for its lead drug candidate, CardiolRx™.
Key Events
-
50% Patient Enrollment Achieved
Cardiol Therapeutics has surpassed 50% patient enrollment in its pivotal Phase III MAVERIC trial evaluating CardiolRx™ for recurrent pericarditis.
-
Key De-risking Milestone
This enrollment milestone represents a significant execution and risk-reduction inflection point for the company's lead registrational program.
-
Full Enrollment Expected Q2 2026
The company anticipates completing full patient enrollment in the MAVERIC trial by the second quarter of 2026.
-
Expanding Clinical Infrastructure
More than 15 leading cardiovascular centers in the U.S. are actively enrolling patients, with additional sites in Europe and Canada being activated to accelerate momentum.
Analysis
This milestone is highly significant for Cardiol Therapeutics as it de-risks the development timeline and increases the probability of success for its lead registrational program. Reaching 50% enrollment in a pivotal Phase III trial demonstrates strong operational execution and investigator confidence in CardiolRx™ for recurrent pericarditis, an underserved patient population. The company anticipates completing full enrollment in Q2 2026, which provides a clear path towards potential regulatory submission and commercialization.
At the time of this filing, CRDL was trading at $0.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $96M. The 52-week trading range was $0.77 to $1.59. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.